Cardioprotective interventions for cancer patients receiving anthracyclines (Q24243021)

3

0 references

Elvira C. van Dalen

1

object named as

Elvira C van Dalen

0 references

Huib N. Caron

2

object named as

Huib N Caron

0 references

Leontien C.M. Kremer

Cochrane Database of Systematic Reviews

4

object named as

Leontien CM Kremer

0 references

publication date

23 April 2008

0 references

published in

0 references

cites work

Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Protective effects of carvedilol against anthracycline-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Prevention of adriamycin-induced cardiotoxicity by prenylamine: a pilot double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Cardioprotective effect of dexrazoxane during treatment with doxorubicin: a study using low-dose dobutamine stress echocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Effect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Cardiac toxicity of daunorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Chelation Therapy in Cardiovascular Disease: Ethylenediaminetetraacetic Acid, Deferoxamine, and Dexrazoxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Doxorubicin cardiotoxicity: possible role of digoxin in its prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Polyoxyethylene-modified superoxide dismutase reduces side effects of adriamycin and mitomycin C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

A clinicopathologic analysis of adriamycin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without compelling evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

New anthracycline antitumor antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Design and baseline characteristics for the ACE Inhibitor After Anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Combination therapy with probucol prevents adriamycin-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

A short multilingual quality of life questionnaire--practicability, reliability and interlingual homogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Risk factors for doxorubicin-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Cardioprotective interventions for cancer patients receiving anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

7 January 2021

Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

7 January 2021

High-dose chemotherapy. Concepts and strategies

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

7 January 2021

Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

7 January 2021

Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

7 January 2021

Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

7 January 2021

Cardioprotection in patients undergoing chemo- and/or radiotherapy for neoplastic disease. A pilot study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

7 January 2021

Anthracycline-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003917.PUB3

7 January 2021

10.1002/14651858.CD003917.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

18425895

1 reference

Consolidated OpenCitations Corpus – April 2017